Novo Nordisk A/S (NYSE:NVO) Stock Holdings Raised by Adero Partners LLC

Adero Partners LLC raised its stake in Novo Nordisk A/S (NYSE:NVO) by 15.4% in the 3rd quarter, Holdings Channel.com reports. The firm owned 5,948 shares of the company’s stock after acquiring an additional 792 shares during the period. Adero Partners LLC’s holdings in Novo Nordisk A/S were worth $708,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of NVO. 1620 Investment Advisors Inc. bought a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth about $25,000. Strategic Investment Solutions Inc. IL bought a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at about $25,000. Gilliland Jeter Wealth Management LLC grew its position in shares of Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after buying an additional 120 shares during the last quarter. Halpern Financial Inc. grew its position in shares of Novo Nordisk A/S by 113.0% during the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after buying an additional 113 shares during the last quarter. Finally, Abound Wealth Management grew its position in shares of Novo Nordisk A/S by 257.4% during the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after buying an additional 157 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 3.4 %

Novo Nordisk A/S stock opened at $101.74 on Friday. The firm has a market cap of $456.56 billion, a PE ratio of 32.93, a P/E/G ratio of 1.31 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm’s 50 day moving average price is $118.58 and its two-hundred day moving average price is $129.59. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on NVO. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.